Page last updated: 2024-11-02

oxaprozin and Acquired Hyperostosis Syndrome

oxaprozin has been researched along with Acquired Hyperostosis Syndrome in 1 studies

Oxaprozin: An oxazole-propionic acid derivative, cyclooxygenase inhibitor, and non-steroidal anti-inflammatory drug that is used in the treatment of pain and inflammation associated with of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; and ARTHRITIS, JUVENILE.
oxaprozin : A monocarboxylic acid that is a propionic acid derivative having a 4,5-diphenyl-1,3-oxazol-2-yl substituent at position 3. It is non-steroidal anti-inflammatory drug commonly used to relieve the pain and inflammatory responses associated with osteoarthritis and rheumatoid arthritis.

Acquired Hyperostosis Syndrome: Syndrome consisting of SYNOVITIS; ACNE CONGLOBATA; PALMOPLANTAR PUSTULOSIS; HYPEROSTOSIS; and OSTEITIS. The most common site of the disease is the upper anterior chest wall, characterized by predominantly osteosclerotic lesions, hyperostosis, and arthritis of the adjacent joints. The association of sterile inflammatory bone lesions and neutrophilic skin eruptions is indicative of this syndrome.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Rothschild, B1
Schils, J1
Lavelle, H1

Other Studies

1 other study available for oxaprozin and Acquired Hyperostosis Syndrome

ArticleYear
Potential therapeutic approach to SAPHO.
    Seminars in arthritis and rheumatism, 2000, Volume: 29, Issue:5

    Topics: Acquired Hyperostosis Syndrome; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents

2000